Financial Performance - The company's revenue for Q1 2022 reached ¥827,689,742.45, representing a 132.24% increase compared to ¥356,396,881.76 in the same period last year[6] - Net profit attributable to shareholders was ¥177,239,159.96, up 232.41% from ¥53,319,684.80 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥173,781,718.39, reflecting a 263.68% increase from ¥47,783,712.76 in the previous year[6] - Basic earnings per share rose to ¥0.4425, a 192.47% increase from ¥0.1513 in the same quarter last year[6] - The operating profit for Q1 2022 was CNY 279,726,066.78, a substantial increase from CNY 77,667,523.86 in Q1 2021[22] Assets and Liabilities - The company's total assets increased by 17.44% to ¥2,472,703,335.31 from ¥2,105,485,351.52 at the end of the previous year[6] - The total liabilities rose to CNY 600,947,135.34, up from CNY 465,671,496.04, marking an increase of 28.9%[20] - The company's total non-current assets amounted to CNY 360,229,253.40, an increase from CNY 338,412,008.50 at the beginning of the year[20] - The company’s fixed assets increased to ¥178,774,710.30 from ¥161,409,330.09, showing a growth of about 10.8%[18] Cash Flow - The net cash flow from operating activities was negative at -¥152,146,040.01, worsening by 1,036.60% compared to -¥13,386,101.96 in the previous year[6] - The cash inflow from operating activities was CNY 400,535,151.96, an increase of 37.5% compared to CNY 291,363,958.94 in the previous period[24] - The cash inflow from investment activities was CNY 371,725,372.46, significantly up from CNY 50,936,315.54 in the previous period[26] - The total cash and cash equivalents at the end of the period were CNY 243,996,627.33, an increase from CNY 176,990,248.95 in the previous period[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 26,865[14] - The largest shareholder, Shanghai Lanwei Investment Co., Ltd., holds 37.34% of the shares, totaling 149,554,017 shares[14] - The company released 2,645,893 restricted shares for trading on March 14, 2022, accounting for 0.6606% of the total share capital[15] - The total number of restricted shares held by major shareholders remains unchanged, with the next release date set for September 13, 2022, for some shareholders[16] Research and Development - Research and development expenses surged by 106.19% to ¥12,493,191.61, indicating a strong commitment to R&D projects[11] - Research and development expenses for Q1 2022 were CNY 12,493,191.61, which is a 106.4% increase from CNY 6,059,086.25 in Q1 2021[22] Business Growth - Accounts receivable increased by 57.31% to ¥1,249,539,766.46, driven by rapid business growth[10] - The company reported a significant increase in sales revenue, leading to a 38.54% rise in cash received from sales of goods and services to ¥396,221,427.14[11] - The company reported a significant increase in accounts payable, which rose to CNY 349,968,289.17 from CNY 253,030,352.86, reflecting a growth of 38.3%[20] - The company signed a significant contract with Hissen Meikang Medical Electronics (Shanghai) Co., Ltd. for a platform business in in vitro diagnostic products, effective from April 1, 2022, to March 31, 2023[15] Other Information - The company has not reported any new product launches or technological advancements in this quarter[15] - The cash and cash equivalents decreased to ¥244,484,061.57 from ¥351,962,422.05 at the beginning of the year, indicating a decline of approximately 30.5%[18] - The company’s cash outflow for purchasing fixed assets was CNY 36,016,213.18, up from CNY 18,915,017.18 in the previous period[26] - The company’s cash outflow for employee payments was CNY 115,869,709.92, increasing from CNY 67,721,931.32 in the previous period[24]
兰卫医学(301060) - 2022 Q1 - 季度财报